Src family kinases: Potential targets for the treatment of human cancer and leukemia

Current Pharmaceutical Design

Volumn 9, Issue 25, 2003, Pages 2043-2059

  Warmuth, Markus ^a   Damoiseaux, Robert ^a   Liu, Yi ^a   Fabbro, Doriano ^b   Gray, Nathanael ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cancerogenesis; Leukemogenesis; Protein kinases; Small molecule kinase inhibitor; Src family kinases

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 3 DIMETHYLAMINO 1 PHENYL 6 PYRIDAZONE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CALPAIN; CGP 76030; IMATINIB; INDOLE DERIVATIVE; ONCOPROTEIN; PDI 180970; PDI 73955; PDI 80970; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; SK 1606; STAT3 PROTEIN; UNCLASSIFIED DRUG; UROKINASE; UVOMORULIN;

BINDING SITE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; COLON CANCER; DEREGULATION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; GENE ACTIVATION; GENE DISRUPTION; GENE MUTATION; GENE OVEREXPRESSION; HEMATOPOIESIS; HUMAN; INHERITANCE; KNOCKOUT GENE; LEUKEMIA; LEUKEMOGENESIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; ONCOGENE SRC; PATHOGENESIS; PLASMACYTOMA; PREVALENCE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

BREAST NEOPLASMS; COLONIC NEOPLASMS; HUMANS; LEUKEMIA; SRC-FAMILY KINASES;

EID: 0141538143     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454126     Document Type: Review

References (186)

1. Blume-Jensen P, Hunter T.Oncogenic kinase signalling. Nature 2001; 411: 355-65.
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S.The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
3. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69: 373-98.
4. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996; 1287: 121-149.
5. Xu W, Harrison S, Eck M. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997; 385: 595-602.
6. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997; 385: 602-609.
7. Erpel T, Superti-Furga G, Courtneidge SA. Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions. Embo J 1995; 14: 963-75.
8. c-src function. J Biol Chem 1989; 264: 20886-20893.
9. Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H. Csk: A protein-tyrosine kinase involved in regulation of Src family kinases. J Biol Chem 1991; 266: 24249-24252.
10. Bennett BD, Cowley S, Jiang S, London R, Deng B, Grabarek J, et al. Identification and characterization of a novel tyrosine kinase from megakaryocytes. J Biol Chem 1994; 269: 1068-1074.
11. c-src. Nature 1991; 351: 69-72.
12. Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y, et al. Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 1993; 73: 125-135.
13. c-src mutated in the carboxy-terminal regulatory domain. Cell 1987; 49: 83-91.
14. Reynolds AB, Vila J, Lansing TJ, Potts WM, Weber MJ, Parsons JT. Activation of the oncogenic potential of the avian cellular src protein by specific structural alterations of the carboxy terminus. Embo J 1987; 6: 2359-2364.
15. Gonfloni S, Williams JC, Hattula K, Weijland A, Wierenga RK, Superti-Furga G. The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src. Embo J 1997; 16: 7261-71.
16. Gonfloni S, Frischknecht F, Way M, Superti-Furga G. Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis. Nat Struct Biol 1999; 6: 760-4.
17. Briggs SD, Smithgall TE. SH2-kinase linker mutations release Hck tyrosine kinase and transforming activities in Rat-2 fibroblasts. J Biol Chem 1999; 274: 26579-83.
18. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999; 21: 187-90.
19. Briggs SD, Sharkey M, Stevenson M, Smithgall TE. SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1. J Biol Chem 1997; 272: 17899-902.
20. Kypta R, Goldberg Y, Ulug E, Courtneidge SA. Association between the PDGF receptor and members of the src family tyrosine kinases. Cell 1990; 62: 481-492.
21. Twamley GM, Hall B, Kypta R, Courtneidge SA. Association of Fyn with the activated PDGF receptor: requirements for binding and phosphorylation. Oncogene 1992; 7: 1893-1901.
22. Schlaepfer DD, Hanks SK, Hunter T, van der Geer P. Integrin-mediated signal transduction linked to Ras pathway by Grb2 binding to focal adhesion kinase. Nature 1994; 372: 786-791.
23. Muthuswamy SK, Muller WJ. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene 1995; 11: 271-9.
24. Muthuswamy SK, Muller WJ. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Oncogene 1995; 11: 1801-10.
25. Linnekin D, DeBerry CS, Mou S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J Biol Chem 1997; 272: 27450-5.
26. Ojaniemi M, Martin SS, Dolfi F, Olefsky JM, Vuori K. The protooncogene product p120(cbl) links c-Src and phosphatidylinositol 3′-kinase to the integrin signaling pathway. J Biol Chem 1997; 272: 3780-7.
27. Warmuth M, Bergmann M, Prieß A, Häuslmann K, Emmerich B, Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997; 272: 33260-33270.
28. Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000; 275: 18581-5.
29. Masaki T, Okada M, Tokuda M, Shiratori Y, Hatase O, Shirai M, et al. Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology 1999; 29: 379-84.
30. Egan C, Pang A, Durda D, Cheng HC, Wang JH, Fujita DJ. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene 1999; 18: 1227-37.
31. Harris KF, Shoji I, Cooper EM, Kumar S, Oda H, Howley PM. Ubiquitin-mediated degradation of active Src tyrosine kinase. Proc Natl Acad Sci USA 1999; 96: 13738-43.
32. Hakak Y, Martin GS. Ubiquitin-dependent degradation of active Src. Curr Biol 1999; 9: 1039-42.
33. Yokouchi M, Kondo T, Sanjay A, Houghton A, Yoshimura A, Komiya S, et al. Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J Biol Chem 2001; 276: 35185-93.
34. Sakamoto KM. Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. Mol Genet Metab 2002; 77: 44-56.
35. Webster MA, Cardiff RD, Muller WJ. Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene. Proc Natl Acad Sci USA 1995; 92: 7849-53.
36. Weissenberger J, Steinbach JP, Malin G, Spada S, Rulicke T, Aguzzi A. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 1997; 14: 2005-13.
37. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W. pp60c-src activation in human colon carcinoma. J Clin Invest 1989; 83: 2025-33.
38. Cartwright CA, Meisler AI, Eckhart W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 1990; 87: 558-62.
39. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993; 91: 53-60.
40. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE. Site-specific differences in pp60c-src activity in human colorectal metastases. J Surg Res 1993; 54: 293-8.
41. Allgayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002; 94: 344-51.
42. Malek RL, Irby RB, Guo QM, Lee K, Wong S, He M, et al. Identification of Src transformation fingerprint in human colon cancer. Oncogene 2002; 21: 7256-65.
43. Nakagawa T, Tanaka S, Suzuki H, Takayanagi H, Miyazaki T, Nakamura K, et al. Overexpression of the csk gene suppresses tumor metastasis in vivo. Int J Cancer 2000; 88: 384-91.
44. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, et al. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 1999; 274: 18428-37.
45. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998; 94: 353-62.
46. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000; 12: 613-20.
47. Wang Y, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem 2000; 267: 3248-54.
48. Dang J, Boyd D, Wang H, Allgayer H, Doe WF, Wang Y. A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Eur J Biochem 1999; 264: 92-9.
49. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002; 26: 767-71.
50. Jones RJ, Avizienyte E, Wyke AW, Owens DW, Brunton VG, Frame MC. Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM12C human colorectal cancer cells. Br J Cancer 2002; 87: 1128-35.
51. Avizienyte E, Wyke AW, Jones RJ, McLean GW, Westhoff MA, Brunton VG, et al. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 2002; 4: 632-8.
52. Nam JS, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 2002; 8: 2430-6.
53. Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 2002; 62: 2669-74.
54. Daigo Y, Furukawa Y, Kawasoe T, Ishiguro H, Fujita M, Sugai S, et al. Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients. Cancer Res 1999; 59: 4222-4.
55. Dehm S, Senger M A, Bonham K. SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett 2001; 487: 367-71.
56. Shimakage M, Kawahara K, Kikkawa N, Sasagawa T, Yutsudo M, Inoue H. Down-regulation of drs mRNA in human colon adenocarcinomas. Int J Cancer 2000; 87: 5-11.
57. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, et al. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 1997; 15: 3083-90.
58. Jacobs C, Rubsamen H. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res 1983; 43: 1696-702.
59. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 1992; 52: 4773-8.
60. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996; 180: 383-8.
61. Biscardi JS, Bels hes AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog 1998; 21: 261-72.
62. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 1994; 8: 23-32.
63. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 1994; 14: 735-43.
64. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998; 243: 503-8.
65. Mazurenko NN, Kogan EA, Zborovskaya IB, Kisseljov FL. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 1992; 28: 372-7.
66. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC Jr, Gallick G. E. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 1999; 5: 2164-70.
67. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003; 88: 73-9.
68. Kumble S, Omary MB, Cartwright CA, Triadafilopoulos G. Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology 1997; 112: 348-56.
69. Takeshima E, Hamaguchi M, Watanabe T, Akiyama S, Kataoka M, Ohnishi Y, et al. Aberrant elevation of tyrosine-specific phosphorylation in human gastric cancer cells. Jpn J Cancer Res, 1991, 82, 1428-35.
70. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21: 7001-10.
71. Bjelfman C, Hedborg F, Johansson I, Nordenskjold M, Pahlman S. Expression of the neuronal form of pp60c-src in neuroblastoma in relation to clinical stage and prognosis. Cancer Res 1990; 50: 6908-14.
72. Bjelfman C, Meyerson G, Cartwright CA, Mellstrom K, Hammerling U, Pahlman S. Early activation of endogenous pp60src kinase activity during neuronal differentiation of cultured human neuroblastoma cells. Mol Cell Biol, 1990; 10: 361-70.
73. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4: 915-24.
74. Overell RW, Watson JD, Gallis B, Weisser KE, Cosman D, Widmer MB. Nature and specificity of lymphokine independence induced by a selectable retroviral vector expressing v-src. Mol Cell Biol 1987; 7: 3394-401.
75. Watson JD, Eszes M, Overell R, Conlon P, Widmer M, Gillis S. Effect of infection with murine recombinant retroviruses containing the v-src oncogene on interleukin 2- and interleukin 3-dependent growth states. J Immunol 1987; 139: 123-9.
76. Anderson SM, Carroll PM, Lee FD. Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle. Oncogene 1990; 5: 317-25.
77. Engelman A, Rosenberg N. bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation. Mol Cell Biol 1990; 10: 4365-9.
78. Kruger A, Anderson SM. The v-src oncogene blocks the differentiation of a murine myeloid progenitor cell line and induces a tumorigenic phenotype. Oncogene 1991; 6: 245-56.
79. Chaturvedi P, Sharma S, Reddy EP. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol Cell Biol 1997; 17: 3295-304.
80. Lowell CA, Soriano P. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev 1996; 10: 1845-57.
81. Chan VW, Meng F, Soriano P, DeFranco AL, Lowell CA. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 1997; 7: 69-81.
82. Lowell C, Niwa M, Soriano P, Varmus H. Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Blood 1996; 87: 1780-1792.
83. Meng F, Lowell CA. Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J Exp Med 1997; 185: 1661-70.
84. Meng F, Lowell CA. A beta 1 integrin signaling pathway involving Src-family kinases, Cb1 and PI-3 kinase is required for macrophage spreading and migration. Embo J 1998; 17: 4391-403.
85. Mocsai A, Ligeti E, Lowell CA, Berton G. Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. J Immunol 1999; 162: 1120-6.
86. Harder KW, Parsons LM, Armes J, Evans N, Kountouri N, Clark R, et al. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity 2001; 15: 603-15.
87. Broudy VC, Lin NL, Liles WC, Corey SJ, O'Laughlin B, Mou S, et al. Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 1999; 94: 1979-86.
88. Wilde A, Beattie EC, Lem L, Riethof DA, Liu SH, Mobley WC, et al. EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake. Cell 1999; 96: 677-87.
89. Jahn T, Seipel P, Coutinho S, Urschel S, Schwarz K, Miething C, et al. Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain. Oncogene 2002; 21: 4508-20.
90. Malek SN, Dordai DI, ReimJ, Dintzis H, Desiderio S. Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Proc Natl Acad Sci USA 1998; 95: 7351-6.
91. Abraham KM, Levin SD, Marth JD, Forbush KA, Perlmutter RM. Thymic tumorigenesis induced by overexpression of p56lck. Proc Natl Acad Sci USA 1991; 88: 3977-81.
92. Keller G, Wagner EF. Expression of v-src induces a myeloproliferative disease in bone-marrow- reconstituted mice. Genes Dev 1989; 3: 827-37.
93. Corey SJ, Anderson SM. Src-related protein tyrosine kinases in hematopoiesis. Blood 1999; 93: 1-14.
94. Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 2000; 254: 1-13.
95. Hallek M, Leif Bergsagel P, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
96. Hallek M, Neumann C, Schaeffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, et al. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol 1997; 25: 1367-77.
97. Schaeffer M, Schneiderbauer M, Weidler S, Tavares R, Warmuth M, de Vos G, et al. Signaling through a Novel Domain of gp130 Mediates Cell Proliferation and Activation of Hck and Erk Kinases. Mol Cell Biol 2001; 21: 8068-81.
98. Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Taniguchi O, et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 2002; 99: 2172-8.
99. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr-abl in myeloid cells. Cancer Res 1996; 56: 3589-3596.
100. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr- Abl kinases. Blood 2003; 101: 664-72.
101. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. Embo J 2002; 21: 5766-74.
102. Shishido T, Akagi T, Ouchi T, Georgescu MM, Langdon WY, Hanafusa H. The kinase-deficient Src acts as a suppressor of the Abl kinase for Cbl phosphorylation. Proc Natl Acad Sci USA 2000; 97: 6439-44.
103. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45.
104. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97: 2440-8.
105. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289:1938-42.
106. Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002; 277: 32214-9.
107. Bohmer FD, Karagyozov L, Uecker A, Serve H, Botzki A, Mahboobi S, et al. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP-site inhibitor STI-571. J Biol Chem 2002; 14: 14.
108. Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996; 384: 484-489.
109. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999; 3: 629-38.
110. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999; 3: 639-48.
111. Mohammadi M, Schlessinger J, Hubbard SR. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 1996; 86: 577-87.
112. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 2001; 106: 745-57.
113. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002; 109: 275-82.
114. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
115. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
116. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002; 8: S14-8.
117. Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol 2001; 28: 9-18.
118. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-52.
119. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-37.
120. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
121. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-25.
122. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-91.
123. Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860-2.
124. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002; 359: 481-6.
125. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-6.
126. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-8.
127. Dorsey JF, Jove R, Kraker AJ, Wu J. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000: 60; 3127-31.
128. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149-53.
129. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002; 21: 8075-88.
130. Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits kit and Bcr-Abl tyrosine kinases. J Biol Chem 2002; 9: 9.
131. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice. Cancer Res 2003; 63: 375-81.
132. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al. Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitorsnag and Imatinib (STI-571). Cancer Res 2002; 62: 4236-43.
133. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000; 19: 5636-42.
134. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001; 2: 467-75.
135. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002; 1602: 114-30.
136. Frame MC, Fincham VJ, Carragher NO, Wyke JA. v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 2002; 3: 233-45.
137. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999; 274: 17209-18.
138. Ram PT, Horvath CM, Iyengar R. Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L Galphao protein. Science 2000; 287: 142-4.
139. Ram PT, Iyengar R. G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation. Oncogene 2001; 20: 1601-6.
140. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001; 98: 7319-24.
141. Ren Z, Schaefer TS. ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J Biol Chem 2002; 277: 38486-93.
142. Cao X, Tay A, Guy GR, Tan YH. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol 1996; 16: 1595-603.
143. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998; 18: 2545-52.
144. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553-8.
145. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene, 2001, 20, 2499-513.
146. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-27.
147. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-95.
148. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
149. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, et al. Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 2001; 276: 31858-62.
150. Park J, Hill MM, Hess D, Brazil DP, Hofsteenge J, Hemmings BA. Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity. J Biol Chem 2001; 276: 37459-71.
151. Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002; 21: 7797-807.
152. Broome MA, Courtneidge SA. No requirement for src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen. Oncogene 2000; 19: 2867-9.
153. Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P. Src family kinases are required for integrin but not PDGFR signal transduction. Embo J 1999; 18: 2459-71.
154. Hanke JE, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, et al. Discovery of a novel, potent, and Src family-selective Tyrosine Kinase Inhibitor. J Biol Chem 1996; 271: 695-701.
155. Waltenberger J, Uecker A, Krol J, Frank H, Mayr U, Bjorge JD, et al. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Circ Res 1999; 85: 12-22.
156. Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999; 6: 671-678.
157. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
158. Bain J, McLauchlan H, Elliot M, Cohen P. The specificities of protein kinase inhibitors, an update. Biochem J 2003; 21.
159. Eyers PA, van den IP, Quinlan RA, Goedert M, Cohen P. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett 1999; 451: 191-6.
160. Liu Y, Shah K, Yang F, Witucki L, Shokat KM. Engineering Src family protein kinases with unnatural nucleotide specificity. Chem Biol 1998; 5: 91-101.
161. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000; 407: 395-401.
162. Bishop AC, Buzko O, Shokat KM. Magic bullets for protein kinases. Trends Cell Biol 2001; 11: 167-72.
163. Habelhah H, Shah K, Huang L, Burlingame AL, Shokat KM, Ronai Z. Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue. J Biol Chem 2001; 276: 18090-5.
164. Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, Shokat KM, et al. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol 2001; 3: 325-30.
165. Shah K, Shokat KM. A Chemical Genetic Screen for Direct v-Src Substrates Reveals Ordered Assembly of a Retrograde Signaling Pathway. Chem Biol 2002; 9: 35-47.
166. Missbach M, Jeschke M, Feyen J, Muller K, Glatt M, Green J, Susa M. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999; 24: 437-49.
167. Missbach M, Altmann E, Widler L, Susa M, Buchdunger E, Mett, H, et al. Substituted 5,7-diphenyl-pyrrolo[2,3d] pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett 2000; 10: 945-9.
168. Altmann E, Missbach M, Green J, Susa M, Wagenknecht HA, Widler L. 7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3d]pyrimidines- potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett 2001; 11: 853-6.
169. Boschelli DH, Wu Z, Klutchko SR, Showalter HD, Hamby JM, Lu GH, et al. Synthesis and tyrosine kinase inhibitory activity of a series of 2- amino-8H-pyrido[2,3-d] pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J Med Chem 1998; 41: 4365-77.
170. Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, et al. 2-Substituted aminopyrido[2,3-d] pyrimidin-7(8H)-ones.
171. Berger D, Dutia M, Powell D, Wissner A, DeMorin F, Raifeld Y, et al. Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors. Bioorg Med Chem Lett 2002; 12: 2989-92.
172. Berger D, Dutia M, Powell D, Wu B, Wissner A, DeMorin F, et al. 8-Anilinoimidazo[4,5-g]quinoline-7-carbonitriles as Src kinase inhibitors. Bioorg Med Chem Lett 2002; 12: 2761-5.
173. Boschelli DH, Wang DY, Ye F, Yamashita A, Zhang N, Powell D, et al. Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles. Bioorg Med Chem Lett 2002; 12: 2011-4.
174. Zhang N, Wu B, Wissner A, Powell DW, Rabindran SK, Kohler C, et al. 4-Anilino-3-cyanobenzo[g]quinolines as kinase inhibitors. Bioorg Med Chem Lett 2002; 12: 423-5.
175. Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, et al. Optimization of 4-phenylamino-3-quinolinecarbo-nitriles as potent inhibitors of Src kinase activity. J Med Chem 2001; 44: 3965-77.
176. Boschelli DH, Wang YD, Ye F, Wu B, Zhang N, Dutia M, et al. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J Med Chem 2001; 44: 822-33.
177. Wang YD, Miller K, Boschelli DH, Ye F, Wu B, Floyd MB, et al. Inhibitors of src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquino-lines and 4-anilinoquinazolines. Bioorg Med Chem Lett 2000; 10: 2477-80.
178. Tian G, Cory M, Smith AA, Knight WB. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochemistry 2001; 40: 7084-91.
179. Chen P, Norris D, Iwanowicz EJ, Spergel SH, Lin J, Gu HH, et al. Discovery and initial SAR of imidazoquinoxa-lines as inhibitors of the Src-family kinase p56(Lck). Bioorg Med Chem Lett 2002; 12: 1361-4.
180. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 2000; 20: 9018-27.
181. Milkiewicz KL, Marsilje TH, Woodworth RP Jr, Bifulco N Jr, Hangauer MJ, Hangauer DG. The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 2: hydroxyindole derivatives. Bioorg Med Chem Lett 2000; 10: 483-6.
182. Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure Fold Des 1999; 7: 651-61.
183. Arnold LD, Calderwood DJ, Dixon RW, Johnston DN, Kamens JS, Munschauer R, et al. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett 2000; 10: 2167-70.
184. Barry OP, Kazanietz MG. Protein kinase C isozymes novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 2001, 7(17): 1725-44.
185. Bradstock KF. The use of hematopoietic growth factors in the treatment of acute leukemia. Curr Pharm Des 2002; 8(5): 343-55.
186. Metcalf CA 3rd, van Schravendijk MR, Dalgarno DC, Sawyer TK. Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr Pharm Des 2002; 8(23): 2049-75.